drugset / Trial / NCT03084250
The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
RandomizedParallel-groupOpen-labelTreatment
Summary
The CHB subjects who are cirrhosis, will be randomized to two groups. The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks. The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Timeline
- Start
- 2017-03-10
- Primary completion
- 2023-04-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 135 ug | — |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
| Comparator | Adefovir | Unknown | — | — |
| Comparator | Entecavir | Small molecule | — | — |
| Comparator | Tenofovir | Small molecule | — | — |